Alzheimer's Disease: Molecularly Based Immunotherapeutics

Ugen, Kenneth E.; Morgan, Dave
November 2001
DNA & Cell Biology;Nov2001, Vol. 20 Issue 11, p677
Academic Journal
Comments on the articles presented on the journal 'DNA and Cell Biology' Volume 20. Relevance of immunization strategies for Alzheimer's disease; Anti-aggregating effect of antibodies against the beta-amyloid component; Characteristics of antibody response to a beta-amyloid 1-42 peptide vaccine.


Related Articles

  • Immunotherapy with �-Amyloid for Alzheimer's Disease: A New Frontier. Schenk, Dale; Seubert, Peter; Ciccarelli, Richard B. // DNA & Cell Biology;Nov2001, Vol. 20 Issue 11, p679 

    Alzheimer's disease (AD) represents the fourth leading cause of death in the U.S. and the leading cause of dementia in the elderly population. Until recently, there was little hope of finding a way to prevent the underlying brain pathology from progressing toward the inevitable conclusion of the...

  • Findings could spoil current approaches to an Alzheimer's cure.  // Long-Term Living: For the Continuing Care Professional;Apr2010, Vol. 59 Issue 4, p12 

    The article focuses on the recent study in "Biological Psychiatry" which states that amyloid beta protein that is consider one of the hallmarks of Alzheimer's disease patients is also present among healthy elderly people.

  • Preface. Nienaber, Vicki L. // Current Pharmaceutical Design;Dec2002, Vol. 8 Issue 28, p1 

    Introduces the articles published in the December 2002 issue of 'Current Pharmaceutical Design.' Biological details of the connection between Alzheimer's disease and �-amyloid plaque formation; Role of proteolytic enzymes in plaque formation; Description of inhibitors of the Hepatitis C...

  • Emerging �-Amyloid Therapies for the Treatment of Alzheimer's Disease. Conway, Kelly A.; Baxter, Ellen W.; Felsenstein, Kavin M.; Reitz, Allen B. // Current Pharmaceutical Design;Feb2003, Vol. 9 Issue 6, p427 

    Alzheimer's Disease (AD) is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioral stability. AD is defined pathologically by extracellular neuritic plaques comprised of fibrillar deposits of �-amyloid peptide (A�) and neurofibrillary tangles...

  • beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality? Talaga, Patrice // Mini Reviews in Medicinal Chemistry;Jul2001, Vol. 1 Issue 2, p175 

    Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential...

  • Fragile minds. Motluk, Alison // New Scientist;2/1/2003, Vol. 177 Issue 2380, p34 

    Investigates the viability of proposed treatments of Alzheimer's disease. Role of the protein amyloid beta in the progress of the disease; Difference of opinion among researchers over the success of treatments that rely on the removal of amyloid beta; Possibility of the protein being...

  • Drug to prevent disease within reach? O'connor, John // McKnight's Assisted Living;Oct2011, Vol. 9 Issue 5, p4 

    The article offers information related to a research which attempts to prevent and treat Alzheimer's disease by inhibiting the accumulation of protein fibres and amyloid beta molecules.

  • Neurodegenerative disease: Putting the brakes on cognitive decline. Smith, Adam // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p507 

    Reports on a study appearing in the May 22, 2003 issue of 'Neuron,' which suggests that antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Immunoreactivity of human sera for aggregated beta-amyloid plaques; Generation of antibodies against aggregated beta-amyloid...

  • Alzheimer disease's double-edged vaccine. Greenberg, S. M.; Bacskai, B.J.; Hyman, B. T. // Nature Medicine;Apr2003, Vol. 9 Issue 4, p389 

    Describes the first autopsy of a brain from an alzheimer disease (AD) patient treated with an experimental amyloid-β (Aβ) vaccine. Uncertainty on the effectiveness of the vaccine against AD; Lesions unaffected by the vaccine; Side effects of the vaccine on patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics